3rd Nov 2008 13:31
|
For immediate release |
3 November 2008 |
ABCAM PLC
("Abcam" or "the Company")
Result of AGM
Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, held its AGM in Cambridge this morning at which all resolutions were duly passed.
For further information please contact:
|
Abcam |
+ 44 (0) 1223 696000 |
|
Jonathan Milner, Chief Executive Officer |
|
|
Eddie Powell, Chief Financial Officer www.abcam.com |
|
|
Numis Securities |
+ 44 (0) 20 7260 1000 |
|
Michael Meade James Black |
|
|
Buchanan Communications |
+ 44 (0) 20 7466 5000 |
|
Mark Court / Mary-Jane Johnson |
Notes for editors
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, UK, with a US office located in Cambridge, Massachusetts and a Japanese office in Tokyo. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third party produced antibodies to academic and commercial users throughout the world with product information provided and ordering available through the Company's website, www.abcam.com. The antibodies are sold under the Abcam brand name. The Company's vision is to build the largest online antibody resource in the world while also ensuring that the antibodies are of high quality and commercially viable. Abcam now has an online catalogue of over 46,000 products, most of which are antibodies, from over 250 suppliers supported by up-to-date and detailed technical data sheets, which are created by the Company. The Company currently employs approximately 184 staff in its three operating companies.
Related Shares:
ABC.L